Search clinical trials for: Bevacizumab (Avastin®)

Total 16115 results

University of Sao Paulo

Completed

Intravitreous Bevacizumab and Standard Metabolic Control for Diabetic Macular Edema - A Contrast Sensitivity Study

Diabetic Macular Edema

Brazil
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.

Liver Cancer

Philippines, Korea, Republic of, Taiwan
Lund University Hospital
Hoffmann-La Roche

Completed

Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- Tarceva (ACT)

Metastatic Colorectal Cancer

Denmark, Sweden
Galectin Therapeutics Inc.

Withdrawn

A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer

Colorectal Cancer

Israel
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Recruiting

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Endometrioid Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Ovarian High Grade Serous Adenocarcinoma | Platinum-Resistant... and other conditions

United States, Canada
Children's Hospital Medical Center, Cincinnati

Completed

A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors (VITAC)

Solid Tumor

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Completed

Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer

Metastatic Breast Cancer

United States
UNICANCER

Completed

Study of Gemcitabine+Platinum Salt+Bevacizumab Combination for Metastatic Collecting Duct Carcinoma (GETUG-AFU 24) (BEVABEL)

Collecting Duct Carcinoma (Kidney)

France
Queen's University
The Physicians' Services Incorporated Foundation

Completed

Bloodstream Absorption of Avastin and Lucentis After Injection Into the Eye

Diabetic Macular Edema

Canada
Hospices Civils de Lyon

Completed

French Evaluation Group Avastin Versus Lucentis (GEFAL)

Age Related Macular Degeneration

France
Hoffmann-La Roche

Withdrawn

A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma

Renal Cell Carcinoma
Georgetown University

Terminated

Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer (ALEXANDRIA)

Metastatic Colorectal Cancer

United States
Hoffmann-La Roche

Terminated

A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma

Multiple Myeloma

Austria
Duke University
Genentech, Inc.

Completed

Radiosurgery and Avastin for Recurrent Malignant Gliomas

Malignant Glioma

United States
Shahid Beheshti University of Medical Sciences

Completed

Intravitreal Bevacizumab for Neovascular Glaucoma (IVB NVG)

Glaucoma | Neovascular

Iran, Islamic Republic of
Hoffmann-La Roche

Terminated

A Study of Circulating Endothelial Cell as Marker for Avastin (Bevacizumab) in Combination With Docetaxel Plus Xeloda (Capecitabine) as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast Cancer

Breast Cancer

Taiwan
Hoffmann-La Roche

Completed

AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer

France, Germany, Spain, Sweden, Russian Federation, Greece, Switzerland, Korea, Republic of, Italy, Netherlands, Turkey, United Arab Emirates
Herbert Hurwitz
National Cancer Institute (NCI)

Completed

Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery

Colorectal Cancer

United States
Rabin Medical Center

Unknown

Phase I/II Study of Weekly Docetaxel and Cisplatin Together With Capecitabine and Bevacizumab in Advanced Gastric Cancer

Advanced Gastric Cancer

Israel
Laboratorios Liomont
Servicios Especializados en Ensayos Clínicos, S.C.

Recruiting

Safety of Effivia®, a Bevacizumab Biosimilar

Metastatic Colorectal Cancer | Metastatic Cervical Cancer | Non Squamous Non Small Cell Lung Cancer

Mexico
Henan Provincial People's Hospital

Not yet recruiting

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma

Glioblastoma

China
Roswell Park Cancer Institute
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Celldex Therapeutics

Recruiting

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Serous Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Platinum-Sensitive Ovarian Carcinoma | Recurrent Fallopian... and other conditions

United States
Merck Sharp & Dohme LLC
Gynecologic Oncology Group; European Network of Gynaecological Oncological...

Active, not recruiting

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

Peritoneal Neoplasms | Ovarian Cancer | Fallopian Tube Cancer

Poland, Korea, Republic of, United States, Australia, Belgium, Brazil, Canada, Chile, Colombia, Czechia, France, Germany, Hungary, Israel, Italy, Japan, Russian Federation, South Africa, Spain, Taiwan, Turkey, Ukraine
Hoffmann-La Roche

Completed

A Study of Avastin (Bevacizumab) in Combination With Thoracic Radiation and Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.

Non-Squamous Non-Small Cell Lung Cancer

Netherlands, United Kingdom
Pharmatech
Sanofi; Genentech, Inc.

Terminated

Phase II Avastin Trial for Stage IIIB/IV NSCLC

Non-small Cell Lung Cancer Stage IIIB | Non-small Cell Lung Cancer Stage IV
Duke University
Sanofi; Hoffmann-La Roche; Genentech, Inc.

Completed

Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma (XAGastric)

Stomach Neoplasms | Neoplasm Metastasis | Esophageal Neoplasms

United States
National Cancer Institute (NCI)

Completed

Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
GlaxoSmithKline

Completed

Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer

Lung Cancer, Small Cell | Recurrent Small-cell Lung Cancer (SCLC)

United States
Ottawa Hospital Research Institute
Sanofi; Pfizer; Hoffmann-La Roche; Ottawa Regional Cancer Foundation

Terminated

A Phase I/II Study of IXO With Bevacizumab in Patients With Metastatic Colorectal Cancer (IXO+A)

Metastatic Colorectal Cancer

Canada
Li Liu

Unknown

VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer

Non Small Cell Lung Cancer | Brain Metastasis

China
Genentech, Inc.

Completed

A Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With Chemotherapy in Previously Treated Metastatic Breast Cancer (RIBBON 2)

Metastatic Breast Cancer
Ritu Salani
Genentech, Inc.

Completed

Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States
Ohio State University Comprehensive Cancer Center
Eli Lilly and Company; Genentech, Inc.

Completed

Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Malignant Solid Neoplasm | Ovarian Endometrioid Adenocarcinoma | Ovarian Undifferentiated Carcinoma | Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Malignant Peritoneal Neoplasm | Endometrial Clear Cell Adenocarcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell... and other conditions

United States
Henan Provincial People's Hospital

Recruiting

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma

Oligodendroglioma

China
National Cancer Institute (NCI)

Active, not recruiting

Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Melanoma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Lung Non-Squamous Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7 | EGFR Exon 19 Deletion Mutation | EGFR NP_005219.2:p.L858R

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Radiation Therapy in Treating Patients With Recurrent Brain Tumors Who Have Undergone Previous Radiation Therapy

Recurrent Brain Neoplasm

United States
Northwell Health

Recruiting

Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM

Glioblastoma | Brain Cancer | Glioblastoma Multiforme | GBM | Glioma, Malignant | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult

United States
GERCOR - Multidisciplinary Oncology Cooperative...

Active, not recruiting

QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters. (COLAGE)

Quality of Life | Metastatic Colorectal Cancer | Elderly Patients

France
M.D. Anderson Cancer Center

Completed

Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)

Glioblastoma | Brain Cancer

United States
Sutro Biopharma, Inc.

Recruiting

A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Ovarian Carcinoma | Ovary Cancer | Primary Peritoneal Carcinoma

United States
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

China
Beijing Mabworks Biotech Co., Ltd.
Betta Pharmaceuticals Co., Ltd.

Completed

mil60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

Metastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Refractory Melanoma | BRAF V600 Wild Type | Intracranial Melanoma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer

Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Recurrent Colorectal Carcinoma | Metastatic Colorectal Carcinoma | Refractory Colorectal Carcinoma

United States
mAbxience Research S.L.
Laboratorio Elea Phoenix S.A.; Libbs Farmacêutica LTDA

Completed

Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients

Metastatic Colorectal Cancer (mCRC)

Argentina, Brazil, India, Spain, Ukraine
The Methodist Hospital Research Institute
Genentech, Inc.

Not yet recruiting

Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria

Hepatocellular Carcinoma | Hepatocellular Cancer

United States
Arjun Balar, MD
Hoosier Cancer Research Network; Roche-Genentech

Terminated

Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer

Urothelial Carcinoma

United States

Search clinical trials for: Bevacizumab (Avastin®)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations